SUMMARY
Staphylococcus aureus is one of the most clinically challenging pathogens whose pathogenicity is attributed to evolutionary adaptations in persistence, virulence, and antibiotic resistance. Indeed, protein synthesis inhibitors (e_g, clindamycin and linezolid) as well as intravenous immunoglobulins (IVIgs) have been tested in the treatment of severe PVL-associated infections with promising results. In the previous work, the authors managed to illustrate the inhibitory effect of ascorbic acid and nicotinamide on PVL cytolytic activity. The authors aim to quantitively examine the effect of ascorbic acid and nicotinamide, individually, on PVL production in the reference strain USA300. The inoculum used . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.